Nuvation Bio Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nuvation Bio Inc. is a global biopharmaceutical company specializing in oncology drug development, focused on addressing significant unmet needs in cancer treatment. The company’s core products include taletrectinib (IBTROZI™), an oral, potent, central nervous system-active ROS1 inhibitor for ROS1-positive non-small cell lung cancer; safusidenib, a brain-penetrant, oral targeted inhibitor of mutant IDH1 for gliomas; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer therapy; and NUV-868, a BD2-selective BET inhibitor. Nuvation also develops proprietary DDC technology that selectively delivers potent anti-cancer agents to tumor cells to improve efficacy and reduce toxicity to healthy tissue. Founded in 2018 and headquartered in New York, the company operates additional offices in San Francisco, Boston, and Shanghai. Recent strategic developments include the acquisition of AnHeart Therapeutics in March 2024, enhancing its clinical pipeline, and securing up to $250 million in non-dilutive financing from Sagard Healthcare Partners in March 2025, which comprises $150 million in royalty interest financing and a senior term loan to support commercialization and pipeline development. Nuvation Bio has published positive Phase 2 clinical results for safusidenib demonstrating durable responses and a high progression-free survival rate in patients with IDH1-mutant glioma. It is preparing for potential U.S. commercial launch of taletrectinib, contingent on FDA approval, supported by its strong cash position and business expansion efforts. The company targets hard-to-treat oncology indications, with a focus on innovative therapies designed to overcome resistance and improve patient outcomes globally.
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB